Oruka Therapeutics (NASDAQ:ORKA) Given “Buy” Rating at HC Wainwright

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued on Thursday, Benzinga reports. They presently have a $120.00 target price on the stock. HC Wainwright’s target price points to a potential upside of 30.96% from the stock’s previous close.

A number of other equities research analysts have also recently commented on ORKA. UBS Group upped their target price on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Weiss Ratings upgraded Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. BTIG Research restated a “buy” rating and set a $151.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Piper Sandler restated an “overweight” rating and set a $180.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Finally, Wedbush reaffirmed an “outperform” rating and set a $165.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $134.30.

Oruka Therapeutics Price Performance

ORKA stock opened at $91.63 on Thursday. Oruka Therapeutics has a 1 year low of $14.66 and a 1 year high of $115.51. The business’s 50-day moving average is $95.11 and its two-hundred day moving average is $69.01. The firm has a market capitalization of $6.07 billion, a P/E ratio of -45.14 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, analysts expect that Oruka Therapeutics will post -2.33 EPS for the current year.

Insider Activity at Oruka Therapeutics

In other Oruka Therapeutics news, SVP Arjun Agarwal sold 10,000 shares of the company’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the completion of the sale, the senior vice president directly owned 15,312 shares in the company, valued at $1,633,177.92. This represents a 39.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 75,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $91.83, for a total transaction of $6,887,250.00. Following the completion of the transaction, the chief executive officer owned 925,580 shares in the company, valued at $84,996,011.40. The trade was a 7.50% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 158,116 shares of company stock valued at $13,523,783 in the last ninety days. 23.49% of the stock is owned by company insiders.

Institutional Investors Weigh In On Oruka Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Sei Investments Co. increased its holdings in Oruka Therapeutics by 136.0% during the 1st quarter. Sei Investments Co. now owns 22,840 shares of the company’s stock worth $1,120,000 after purchasing an additional 13,164 shares during the last quarter. Handelsbanken Fonder AB bought a new position in shares of Oruka Therapeutics during the second quarter valued at approximately $15,313,000. Dimensional Fund Advisors LP acquired a new position in Oruka Therapeutics during the 1st quarter valued at approximately $5,543,000. The Manufacturers Life Insurance Company grew its position in shares of Oruka Therapeutics by 18.3% during the first quarter. The Manufacturers Life Insurance Company now owns 72,563 shares of the company’s stock worth $3,559,000 after acquiring an additional 11,205 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Oruka Therapeutics in the first quarter valued at approximately $1,811,000. 56.44% of the stock is owned by institutional investors and hedge funds.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.